Navigation Links
Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
Date:5/21/2008

BERKELEY HEIGHTS, N.J., May 21 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that multiple abstracts featuring its lead oncology products will be featured at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30 - June 3, 2008.

The abstracts include the following:

-- Initial Phase 1 Clinical and Pharmacokinetic Assessment of G4544, an

oral gallium-containing Compound. Poster # 53C Abstract No: 8592

Saturday, May 31, 2008.

-- A Phase I/II Study to Determine the Feasibility and Efficacy of the

Triple Combination of Oblimersen (OBL), Abraxane (ABX), and

Temozolomide (TMZ) in Metastatic Melanoma and Normal LDH. Poster # 16

Abstract No: 9027 Sunday, June 1, 2008.

-- Effect of the Addition of Oblimersen (Bcl-2 antisense) to

Fludarabine/Cyclophosphamide for Relapsed/Refractory Chronic

Lymphocytic Leukemia (CLL) on Survival in Patients Who Achieve CR/nPR:

Five-year Follow-up from a Randomized Phase III Study. Abstract # 7008

Monday, June 2, 2008.

-- Prognostic Impact of Baseline LDH on Survival Independent of Tumor

Burden in Advanced Melanoma: Results of Phase III Trial of

Oblimersen-Dacarbazine (OBL-DTIC) vs. DTIC. (Publication).

-- Short IV Infusion of Oblimersen (OBL) in Patients with Solid Tumors:

Safety and Pharmacokinetics. (Publication).

-- Pharmacokinetics of Albumin-bound Paclitaxel (ABX) in combination with

Temozolomide (TMZ) and Oblimersen Sodium (OBL) in Patients with

Advanced Melanoma. (Publication).

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medici
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Clinical Programs Featured at American Society of Hematology Meeting
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Genta Receives Key Patent Related to Oral Gallium Compound G4544
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
(Date:8/29/2014)... Research and Markets  has announced the addition ... report to their offering. The Central ... the largest segments of pharmaceuticals industry. The numbers of CNS ... therapies were unable to meet the market requirements. There has ... disorder, especially over the past two decades. The market for ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... , EMERYVILLE, Calif., Nov. 5 Bionovo, Inc. (Nasdaq: ... focused on the unmet needs in women,s health and ... for the three months ended September 30, 2009. , ... 2009, Bionovo successfully completed a public offering and issued ...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be ... Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. ... president of finance and chief financial officer at Amylin Pharmaceuticals, ... of the presentation will be webcast and a recording will ...
Cached Medicine Technology:Bionovo Announces Third Quarter 2009 Highlights and Financial Results 2Bionovo Announces Third Quarter 2009 Highlights and Financial Results 3Bionovo Announces Third Quarter 2009 Highlights and Financial Results 4Bionovo Announces Third Quarter 2009 Highlights and Financial Results 5Bionovo Announces Third Quarter 2009 Highlights and Financial Results 6Bionovo Announces Third Quarter 2009 Highlights and Financial Results 7Bionovo Announces Third Quarter 2009 Highlights and Financial Results 8Bionovo Announces Third Quarter 2009 Highlights and Financial Results 9
(Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... to store, retrieve, organize and analyze biological and ... comprises of the activity of developing software tools ... is not to be confused with biological computation. ... the better understanding of biology can its related ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
(Date:9/1/2014)... September 01, 2014 Pastor Thompson is an ... at Eagle Village. He is a licensed minister through the ... the past twenty years in New Mexico, Colorado and North ... of marriage this year. He also has two beautiful ... B.S. in Pastoral Ministry from Nazarene Bible College, in Colorado ...
(Date:9/1/2014)... 01, 2014 Psychogenic Non-epileptic Seizures (PNES), ... psychological disorder that can have devastating effects on those ... epileptic seizures however, they are not produced by electrical ... It is estimated that the numbers of persons ... multiple sclerosis. , Dr. Lorna Myers, Director ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... key part of health care reform that requires all Americans ... people gaining coverage, but would not dramatically increase the cost ... comes as the U.S. Supreme Court prepares to hear arguments ... key provision of 2010,s Affordable Care Act. According ...
... News) -- Using an autoinjector device to deliver ... effective way to treat status epilepticus, a prolonged type ... report. "This is a very important study for ... French, first vice president of the American Epilepsy Society. ...
... , WEDNESDAY, Feb. 15 (HealthDay News) -- How fast you ... help predict your odds for dementia or stroke later in life, ... can be easily performed in a doctor,s office, noted study author ... and her colleagues tested the walking speed, hand grip strength and ...
... Hospitalization for underage drinking is common in the United States, ... total cost for these hospitalizations is about $755 million per ... found geographic and demographic differences in the incidence of alcohol-related ... Journal of Adolescent Health . Of the ...
... may be receiving the highest exposure to nanoparticles of titanium ... than adults, according to a new study. Published in ACS, ... first broadly based information on amounts of the nanomaterial ... and environmental effects in a wide range of consumer ...
... -- About 27 million Americans aged 50 and older have ... hearing aid, a new study finds. However, many people ... insurance, they don,t receive training in integrating hearing aids into ... part of aging and not a major concern, according to ...
Cached Medicine News:Health News:Ending individual mandate would not dramatically hike insurance prices, study finds 2Health News:Ending individual mandate would not dramatically hike insurance prices, study finds 3Health News:'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study 2Health News:'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study 3Health News:Can Walking Speed, Hand Grip in Middle Age Predict Dementia Risk? 2Health News:Mayo Clinic: Hospitalization of US underage drinkers common, costs $755 million a year 2Health News:Millions of Americans Have Untreated Hearing Loss: Study 2
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Soft, autoclavable, and without conformer....
Size: Small. 20.50 mm by 22.00 mm. Clear lucite. Supplied sterile....
... x 100 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: